A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: HER2-positive Metastatic Breast Cancer
Interventions: DRUG: TQ-B211|DRUG: Herceptin®|DRUG: docetaxel
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.